Clinical Studies Evaluation Agreement Between AH and P&G

Alimentary Health Announces Additional Clinical Studies Evaluation Agreement with Procter & Gamble

Alimentary Health is a leader in pioneering the development of safe and effective therapeutics for GI and other indications. AH probiotic technology such as Bifantis® (Bifidobacterium infantis 35624), has been clinically proven to manage a full range of episodic digestive upsets, including constipation, diarrhea, abdominal discomfort, urgency, gas and bloating. Bifantis is only found in the daily probiotic supplement Align® which is being marketed by P&G in the US under a current licensing agreement with AH. This new Clinical Studies Agreement is designed to further explore the clinical benefits of AH technology over the next several years.

Under the terms of the agreement, AH would be entitled to receive undisclosed milestone payments based upon clinical performance.

Barry Kiely, CEO of Alimentary Health, said "today's announcement that Procter & Gamble has chosen to undertake further clinical evaluation for Alimentary's probiotic technology reflects the successful relationship we have had with the company since 2001. This project will focus on evaluating the clinical benefits of AH's probiotic technology for gastrointestinal indications. We are delighted to extend and expand our relationship with Procter & Gamble and look forward to updating our stakeholders on our progress,"

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland